Supplementary Table S4 from Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
posted on 2023-03-30, 23:41authored byLale Erdem-Eraslan, Martin J. van den Bent, Youri Hoogstrate, Hina Naz-Khan, Andrew Stubbs, Peter van der Spek, René Böttcher, Ya Gao, Maurice de Wit, Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp, Laurens V. Beerepoot, Monique C.J. Hanse, Jan Buter, Aafke H. Honkoop, Bronno van der Holt, René M. Vernhout, Peter A.E. Sillevis Smitt, Johan M. Kros, Pim J. French